Treatment of eight dogs with nasal tumours with alternating doses of doxorubicin and carboplatin in conjunction with oral piroxicam

Langova, V.; Mutsaers, Anthony J.; Phillips, Brenda; Straw, Rodney C.

doi:10.1111/j.1751-0813.2004.tb12151.x

Cited by 56 publications

(44 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most frequent nasal neoplasias are adenocarcinomas, SCCs and TCCs (Saunders et al 2003;, Lana et al 2004;Rassnick et al 2006). Many studies and reports have described TCC in the nasal cavity and its prevalence among nasal neoplasias ranges from 12-50% (Theon et al 1993;Borzacchiello et al 2004;Langova et al 2004;Impellizeri and Esplin 2008;Vanherberghen et al 2009). …”

Section: Discussionmentioning

confidence: 99%

“…RT has been shown to improve survival time in dogs with sinonasal tumours (Elliot and Mayer 2009). While surgery and chemotherapy have been used as sole treatment modalities for canine nasal tumours (Langova et al 2004), RT used alone or in combination with surgery or chemotherapy can significantly improve patient survival time (Theon et al 1993;Lana et al 2004;Elliot and Mayer 2009). The availability of RT equipment is currently limited for many vet practitioners.…”

Section: Discussionmentioning

confidence: 99%

“…The availability of RT equipment is currently limited for many vet practitioners. Additionally, it may be declined by some owners due to the cost, acute side effects or the three-to four-week separation from their pet that may be required (Langova et al 2004). In this case, the patient received chemotherapy with cisplatin and piroxicam.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Cox-2 expression after chemotherapy in a canine nasal transitional cell carcinoma: a case report

Ojeda¹,

Moroni²,

Mieres³

et al. 2013

Vet. Med. - Czech

View full text Add to dashboard Cite

An eight year-old mixed breed dog was referred for evaluation with chronic sneezing, epistaxis and nasal bone deformation. A clinical exam revealed a deformity of the left nasal bone. Cytological evaluation of the nasal cavity showed round and cuboid cells in different stages of maturation. Computed tomography images identified a diffuse soft tissue mass in the nasal cavity. The histopathological diagnosis was transitional cell carcinoma. Chemotherapy with cisplatin and piroxicam was initiated. Computed tomography was used to follow the chemotherapy outcome. As many nasal carcinomas express COX-2, its expression was evaluated before and after chemotherapy. Computed tomography revealed a significant reduction of the tumour mass. Inmunohistochemistry showed a marked decrease in COX-2 expression and after 1120 days, the dog remained without clinical signs. Thus, the use of piroxicam and cisplatin is revealed to be effective in the treatment of a nasal transitional carcinoma in a dog. Also, it is possible to postulate that a decrease in COX-2 expression after chemotherapy may be regarded as an indication for a good response to the treatment and favourable outcome. To the authors' knowledge this is the first report that evaluates COX-2 expression after chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cox-2 expression after chemotherapy in a canine nasal transitional cell carcinoma: a case report

Ojeda¹,

Moroni²,

Mieres³

et al. 2013

Vet. Med. - Czech

View full text Add to dashboard Cite

show abstract

“…Canine SCC is difficult to make an early diagnosis and radically cure because of the surgical risks associated with nasal and facial SCC and/or achieving wide surgical margins, poor response to chemotherapy, and difficulty with irradiation. Eight canine patients with nasal and facial tumors reportedly demonstrated complete remission following a chemotherapeutic protocol using a combination of doxorubicin, carboplatin and oral piroxicam [11]. Radiochemotherapy has been reported to have life-extending efficacy in SCC [10]; however, such cancers are difficult to treat in veterinary practice.…”

mentioning

confidence: 99%

Expression of SART-1 mRNA in Canine Squamous Cell Carcinomas

Takaishi¹,

Yoshida²,

Nakagaki³

et al. 2008

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. SART-1, a squamous cell carcinoma (SCC) antigen recognized by cytotoxic T lymphocytes, has been useful in human cancer therapy. The SART-1 259 peptide is a potential candidate for vaccine. The present study examined an orthologue of the mRNA coding this peptide in canine SCCs. Specimens were obtained from seven canine patients with SCC, and the mRNA was isolated from the samples. The SART-1 and beta-actin genes were amplified by reverse-transcription polymerase chain reaction, using the isolated mRNA as a template. Canine SART-1 was amplified in six of the seven specimens, while beta-actin was detected in all the samples. In dogs, carcinomas expressing SART-1 could be a target for cytotoxic T lymphocyte mediated immunotherapy. KEY WORDS: cancer immunotherapy, Canis lupus familiaris, RT-PCR, SART-1, squamous cell carcinoma.

show abstract

“…O mastocitoma também já foi descrito, porém é raro (PATNIAK, 1989;LANA;WITHROW, 2001;YOSHITOSHI, 2003;LANGOVA et al, 2004;SAKO et al, 2005).…”

Section: Neoplasias Intranasais E Nasossinusaisunclassified

<b>Estudo clínico-cirúrgico, tomográfico e imuno-histoquímico de cães com neoplasia intranasal tratados com rinotomia e quimioterapia</b>

Auler¹

View full text Add to dashboard Cite

DEDICATÓRIAAos meus amados e maravilhosos filhos Pedro e Guilherme pela compreensão e paciência para que eu concluísse este trabalho.Ao meu amado marido André por seu amor, paciência, apoio e compreensão em todos estes anos durante minha trajetória profissional.A minha maravilhosa mãe Olivia Teresa pelo seu imensurável amor por mim e meus filhos, e por seu indescritível e incomparável apoio em todas as minhas realizações pessoais e profissionais.A minha querida filha do coração Rafaella.Ao meu querido orientador Prof. Dr. Angelo Stopiglia por todos seus ensinamentos, confiança, apoio, paciência e compreensão durante este e demais trabalhos.Ao meu pai José Otávio por seu apoio em minhas realizações pessoais e profissionais.A todos os cães e tutores pela confiança e perseverança no tratamento contra o câncer. AGRADECIMENTOSÀ Deus por sempre me proteger e iluminar meu caminho À Profa. Dra. Ana Carolina Brandão de Campos Fonseca Pinto, pela amizade, dedicação, auxílio, incentivo, conselhos e colaboração fundamental na realização deste trabalho, e também por conceder a sala para realização das rinoscopias. Aos amigos e pós-graduandos Valter Winkel e Ana Luiza Nairismagi Alves, pelos ensinamentos e colaboração na realização das imunohistoquímicas. These results were promising as the expression of cellular markers in malignant nasal tumors dog, as well as the use of staging system and treatment in relationship with survival time and remission of animals affected by this disease.

show abstract

Treatment of eight dogs with nasal tumours with alternating doses of doxorubicin and carboplatin in conjunction with oral piroxicam

Abstract: This chemotherapy protocol was efficacious and well tolerated in this series of eight cases of canine nasal tumours.

Cited by 56 publications

References 20 publications

Cox-2 expression after chemotherapy in a canine nasal transitional cell carcinoma: a case report

Cox-2 expression after chemotherapy in a canine nasal transitional cell carcinoma: a case report

Expression of SART-1 mRNA in Canine Squamous Cell Carcinomas

<b>Estudo clínico-cirúrgico, tomográfico e imuno-histoquímico de cães com neoplasia intranasal tratados com rinotomia e quimioterapia</b>

Contact Info

Product

Resources

About